Summary
Parkinsonian patients with orthostatic hypotension and dizziness due to usual antiparkinson therapy have been treated with the precursor ammoacid of noradrenaline, DL-3,4-threo-dihydroxyphenylserine (DL-3,4-threo-DOPS). Oral and intravenous administration improved these side effects significantly. A combined treatment of L-dopa, peripheral decarboxylase inhibitor and DL-3,4-threo-DOPS seems to be of benefit with respect to akinesia and orthostatic hypotension.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bartholini, G., Constantinidis, J., Puig, M., Tissot, R., Pletscher, A. The stereoisomers of 3,4-dihydroxyphenylserine as precursor of norepinephrine. J. Pharmacol. Exp. Ther.193, 523–532 (1975).
Bell, C., Gillespie, J. S. Dopamine and noradrenaline levels in peripheral tissues of several mammalian species. J. Neurochem.36, 703–706 (1981).
Birkmayer, W., Hornykiewicz, O. Der Dioxyphenylalanin (L-dopa) Effekt beim Parkinson Syndrom des Menschen. Arch. Psychiatr.203, 560–571 (1962).
Birkmayer, W., Neumayer, E. Die moderne medikamentöse Behandlung des Parkinsonismus. Z. Neurol.202, 257–280 (1972).
Bogaert, M. G., Buylaert, W. A., De Schaerpdryver, A. F., Willems, J. L. Vascular effects of bromocriptine in the hindlimb of the dog. Brit.J. Pharmacol.63, 340P-341P (1978).
Chalmers, J. P., Reid, J. L. Participation of central noradrenergic neurons in arterial baroreceptor reflexes in the rabbit. Circulat. Res.31, 789 (1972).
Clark, B. J., Scholtysik, G., Flückiger, E. Cardiovascular actions of bromocriptine. Acta Endocrinol. (Kbh.)88 (Suppl. 216), 75–81 (1978).
Ehringer, H., Hornykiewicz, O. Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des Extrapyramidalen Systems. Klin. Wschr.38, 1236–1239 (1960).
Farley, I. J., Hornykiewicz, O. Noradrenaline in subcortical brain regions of patients with Parkinson's disease and control subjects. In: Advances in Parkinsonism (Birkmayer, W., Hornykiewicz, O., eds.), pp. 178–185. Basle: Editiones Roche. 1976.
Hornykiewicz, O. Mechanism of action of L-dopa in parkinsonism. Adv. Neurol.2, 1–11 (1973).
Hornykiewicz, O. Motor aspects of basal ganglia disorders: the example of Parkinson's disease. In: Neuro-Psychopharmacology (Deniker, P., Radouco-Thomas, C., Villeneuve, A., eds.), pp. 715–718. Oxford-New York: Pergamon Press. 1978.
De Jong, W., Zandberg, P., Wijen, H.: Catecholamines in the nucleus tractus solitarii (NTS) and blood pressure control. In: Nervous system and hypertension (Meyer, P., Schmitt, H., eds.), pp. 165–172. Wiley-Flammarion. 1979.
Kopp, N., Denoroy, L., Tommasi, M., Gay, N., Chazot, G., Renaud, B. Increase in noradrenaline-synthesizing enzyme activity in medulla oblongata in Parkinson's disease. Acta Neuropathol.56, 17–21 (1982).
Lloyd, K. G., Davidson, L., Hornykiewicz, O. The neurochemistry of Parkinson's disease: effect of L-dopa therapy. J. Pharm. Exp. Ther.195, 453–464 (1975).
Lokhandwala, M. F., Tadepalli, A. S., Jandhyala, B. S. Cardiovascular actions of bromocriptine: evidence for a neurogenic action. J. Pharmacol. Exp. Ther.211, 620–625 (1979).
van Loon, G. R., Sole, M. J., Ruse, J. L. Effects of bromocriptine on plasma catecholamines in normal men. Neuroendocrinology28, 425 (1979).
McDowell, F. H., Lee, J. E. Levodopa, Parkinson's disease and hypotension. Ann. intern. Med.72, 751 (1970).
Nagatsu, T., Kato, T., Numata (Sudo), Y., Ikuta, K., Sano, M., Nagatsu, I., Kondo, Y., Inagaki, S., Iizuka, R., Hori, A., Narabayashi, H.: Phenyletha-nolamine-N-methyltransferase and other enzymes of catecholamine metabolism in human brain. Clin. Chim. Acta75, 221–232 (1977).
Nagatsu, T., Kato, T., Nagatsu, I., Kondo, Y., Inagaki, S., Iizuka, R., Narabayashi, H. Catecholamine-related enzymes in the brain of patients with parkinsonism and Wilson's disease. In: Advances in Neurology, Vol. 24 (Poirier, L. J., Sourkes, T. L., Bedard, P. J., eds.), pp. 283–292. New York: Raven Press. 1979.
Narabayashi, H., Kondo, T., Hayashi, A., Suzuki, T., Nagatsu, T. L-Threo-3,4-dihydroxyphenylserine treatment for akinesia and freezing of parkinsonism. Proc. Japan Acad.B 57, 351–354 (1981).
Nilsson, A., Hökfelt, B. Effect of the dopamine agonist bromocriptine on blood pressure, catecholamines and serum activity in acromegalics at rest, following exercise and during insulin induced hypoglycemia. Acta Endocrinol. (Kbh.)88 (Suppl. 216), 83–96 (1978).
Reid, J. L., Greenacre, K., Teychenne, P. F. Cardiovascular actions of L-dopa and dopaminergic agonists in Parkinsonism. In: Advances in Parkinsonism (Birkmayer, W., Hornykiewicz, O., eds.), pp. 566–573. Basle: Editiones Roche. 1976.
Riederer, P., Birkmayer, W., Seemann, D., Wuketich, St. Brain-noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson's syndrome. J. Neural Transm.41, 241–251 (1977).
Riederer, P., Rausch, W.-D., Birkmayer, W., Jellinger, K., Danielczyk, W. Dopamine-sensitive adenylate cyclase activity in the caudate nucleus and adrenal medulla in Parkinson's disease and in liver cirrhosis. J. Neural Transm. Suppl.14, pp. 153–162. Wien-New York: Springer. 1978.
Taylor, A. A., Fennell, W. H., Feldman, M. B., Brandon, T. A., Ginos, J. Z., Mitchell, J. R. Activation of peripheral dopamine presynaptic receptors lowers blood pressure and heart rate in dogs. Hypertension5, 226–234 (1983).
Weiss, J. L., Ng, L. K. Y., Chase, T. N. Long-lasting dyskinesia induced by levodopa. Lanceti, 1016 (1971).
Youdim, M. B. H. In vivo, noradrenaline is a substrate for rat brain monoamine oxidase A and B. Brit. J. Pharmacol.79, 477–480 (1983).
Ziegler, M. G., Lake, C. R., Williams, A. C., Teychenne, P. F., Shoulson, I., Steinsland, O. Bromocriptine inhibits norepinephrine release. Clin. Pharmacol. Ther.25, 137–142 (1979).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Birkmayer, W., Birkmayer, G., Lechner, H. et al. DL-3,4-threo-DOPS in Parkinson's disease: Effects on orthostatic hypotension and dizziness. J. Neural Transmission 58, 305–313 (1983). https://doi.org/10.1007/BF01252816
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF01252816